At CIIE, NZ business owners take the pulse of bilateral trade

At CIIE, NZ business owners take the pulse of bilateral trade

Summary

At the ninth China International Import Expo in Shanghai in November 2026, New Zealand oral probiotic company Bliss Technologies showcased its 'oral microscope' at the New Zealand pavilion, which can test oral bacteria in one minute. Visitors can swab an oral sample to observe differences in the oral environment before and after taking probiotics. Wang Siwei, head of Greater China for New Zealand's BC Pharmacy Group, has exhibited for nine consecutive years.

The Bliss oral probiotic products he promoted this year have seen rapid sales growth since entering China in 2025. He invited company CEO Scott Johnson to the expo and arranged multiple e-commerce livestreams. Wang said he is used to treating the expo as the first 'big show' for overseas products launching in China, and treats inviting overseas company executives to attend as a one-stop 'experience camp' to feel the vast Chinese market, arranging market research activities to promote deep cooperation between New Zealand companies and Chinese supply chains.

He said an advanced oral probiotic product undergoing clinical trials in China is expected to debut in the Chinese market next year, and Chinese social media influencers will later be invited to New Zealand factories for source-tracing livestreams. Wang believes China's health sector is developing toward professional and clinical segmented tracks, and deep cooperation between Chinese and New Zealand companies in research commercialisation, industrial chains and supply chains will provide cooperation opportunities for overseas Chinese business owners.

Commentary

New Zealand oral probiotic brand Bliss Technologies is accelerating its entry into the Chinese market through the CIIE platform. Its products have seen rapid sales growth since entering in 2025, reflecting a shift in China's health sector toward professional and clinical segmented tracks. For New Zealand SME owners, this case demonstrates a viable path to tap consumer markets in China's second- and third-tier cities through cross-border e-commerce and livestreaming channels.

China has a complete supply chain and huge consumer potential, while New Zealand has advantages in natural health product R&D. The two sides have complementary space in research commercialisation and industrial chain cooperation. However, New Zealand companies also need to note that China's market is highly competitive.

European and American brands already have first-mover advantages in clinical validation and brand recognition, and Chinese local companies are catching up quickly. Therefore, relying solely on imported products may not be sustainable. A more viable strategy is to conduct deep R&D cooperation with Chinese partners, use Chinese clinical data to optimise formulations, and build consumer trust through social e-commerce.

As a platform for product debut and market testing, the CIIE's value lies not only in short-term sales but also in helping New Zealand business owners intuitively understand Chinese consumer needs and channel characteristics, thereby formulating more precise market entry strategies.

Keywords: CIIE, New Zealand, oral probiotics, Bliss Technologies, Wang Siwei, Scott Johnson, BC Pharmacy Group, health sector, cross-border e-commerce livestreaming, China-New Zealand trade cooperation


Photo by kewl on Pixabay

Source: HKcna.hk

Disclaimer: This article is compiled from publicly available sources for general information only. The analysis and commentary are editorial opinions. MiDeer Observer does not guarantee the accuracy or completeness of the information provided. Readers should seek independent professional advice before relying on this content, or contact us for more information.

Leave a Reply

Your email address will not be published. Required fields are marked *